Choosing initial MS therapy; personal, disease, and medication factors

Area of Science:

• Neurology
• Immunology
• Neuroimmunology

Background:

• Early intervention with disease-modifying therapy (DMT) in newly diagnosed relapsing multiple sclerosis (RMS) presents the optimal window to impact long-term disease trajectory.
• Prognostic indicators for individual patients, especially those with mild presentations, remain limited in reliability.
• Treatment decisions involve considering personal factors, disease characteristics, and current DMT efficacy data.

Purpose of the Study:

• To review factors influencing the choice of initial disease-modifying therapy for patients with newly diagnosed relapsing multiple sclerosis.
• To evaluate current disease-modifying therapies based on efficacy and suitability for first-line treatment.

Main Methods:

• Review of personal factors relevant to treatment selection.
• Analysis of disease presentation characteristics impacting prognosis.
• Evaluation of clinical data on the efficacy of available disease-modifying therapies.

Main Results:

• Personal factors and disease presentation characteristics are important but prognostication remains challenging.
• Current data suggest a benefit in offering high-efficacy disease-modifying therapies as a first-line treatment for most patients with newly diagnosed RMS.
• The efficacy of available DMTs varies, supporting a tiered approach to treatment selection.

Conclusions:

• Initiating high-efficacy disease-modifying therapy upfront is the preferred strategy for the majority of newly diagnosed relapsing multiple sclerosis patients.
• This approach maximizes the opportunity to alter the disease course and improve long-term outcomes.
• Further research into reliable individual prognostication may refine future treatment decisions.